AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s lung cancer drug, Tagrisso, has been approved by the FDA for Stage III EGFR-mutated non-small cell lung cancer, after showing a significant extension in median progression-free survival during the LAURA Phase III trial. The treatment is aimed at patients with specific EGFR mutations who have not progressed after chemoradiation therapy. Tagrisso is already in use for various stages of EGFR-mutated NSCLC and continues to be evaluated in ongoing global trials.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
